Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 11/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945261 | 0.82 | MKNK1 (0.47) | LRRK2MKNK1MKNK2IKBKBCHEK2 | |
| SCHEMBL944530 | 0.77 | MKNK1 (0.47) | LRRK2MKNK1MKNK2IKBKBCHEK2 | |
| SCHEMBL945364 | 0.75 | IKBKB (0.52) | MKNK1MKNK2IKBKBCHEK2LMNA | |
| SCHEMBL946827 | 0.75 | MKNK1 (0.47) | MKNK1MKNK2IKBKBCHEK2LMNA | |
| SCHEMBL947978 | 0.74 | MKNK1 (0.53) | LRRK2MKNK1MKNK2IKBKBCHEK2 | |
| SCHEMBL945200 | 0.74 | MKNK1 (0.51) | MKNK1MKNK2IKBKBCHEK2LMNA | |
| SCHEMBL944217 | 0.74 | MKNK1 (0.51) | MKNK1MKNK2IKBKBCHEK2LMNA | |
| SCHEMBL947436 | 0.73 | MKNK1 (0.45) | MKNK1MKNK2IKBKBCHEK2LMNA | |
| SCHEMBL944046 | 0.72 | MKNK1 (0.47) | MKNK1MKNK2IKBKBCHEK2LMNA | |
| SCHEMBL233227 | 0.72 | MKNK1 (0.53) | MKNK1MKNK2IKBKBCHEK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9586932-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9067933-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8598360-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8552196-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | LRRK2 117/4885MKNK1 90/4885MKNK2 94/4885 |
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | LRRK2 117/4885MKNK1 90/4885MKNK2 94/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | LRRK2 131/4885MKNK1 86/4885MKNK2 92/4885 |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | LRRK2 117/4885MKNK1 90/4885MKNK2 94/4885 |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, MAP3K6 | LRRK2 118/4885MKNK1 89/4885MKNK2 92/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | LRRK2 117/4885MKNK1 90/4885MKNK2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.